Objective: To evaluate the effect of bromocriptine on motor impairment, functional disabilit and cognitive impairment 5, 10, and 15 of bromocriptine therapy in patients with hemispheric ischemic stroke using the clinical evaluation guided by the hemispheric stroke scale (HSS).

Background: Bromocriptine has been shown to improve cognitive abnormalities in chronic phase of ischemic stroke. Furthermore, a possible role for bromocriptine in the treatment of motor symptoms after ischemic stroke was investigated but not proven yet up to now.

Methods: We conduct a double blinded clinical trial of bromocriptine (2,5 mg twice a day) or placebo to a group of patients with acute ischemic stroke. Changes of motor performance, cognitive impairment and functional disability are evaluated up to 20 days according to the HSS and modified Rankin scale (mRS). Laboratory tests (stroke risk factors, ECG, chest x-ry) were performed before the study enter and repeated whenever apropriate. Hemispheric ischemic stroke was confirmed by a CT scan.

Results: The mean age of currently enrolled patiens was 69.0 (SD 7.8) Bromocriptine was well tolerated and seemed safe, the adverse effects/no of patients excluded was coparable between bromocriptine and placebo groups. Nausea was detected in 2/" patients in bromocriptine/placebo group. there were 3 patients excluded in the placebo group (medical reasons) and 2 in the bromocriptine group (transported to another location, changing mind about study collaboration). At 15 days improvement was close to significance regarding motor functions in the bromocriptine group. Othere results were not conclusive yet.

Conclusions: Our data suggest an effect of bromocriptine on faster motor improvement in acute ischemic stroke.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/may-early-introduction-of-dopaminergic-agonists-improve-simptoms-after-ischemic-stroke-the-interim-report/